Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary data from the phase 1/2 study of TP-3654, an investigational selective PIM1 kinase inhibitor, showed cytokine reduction and clinical responses in relapsed/refractory myelofibrosis (MF)
    Meeting Abstract

    El Chaer, F.; Rein, L.; Shimoda, K.; Yuda, J.; Haque, T.; McCloskey, J.; Takami, A.; Fukaya, M.; Shirane, S.; Kabir, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes with venetoclax (VEN) in patients with acute myeloid leukemia (AML) from COTA, a US RW evidence database
    Meeting Abstract

    Stein, E.; Hodzic, S.; Owusu, H.; Pathak, D.; Zhou, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Post hoc analysis of patient responses by T315I mutation status from the 3-year update of the optic trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Molecular response of ≤10% BCR::ABL1IS is predictive of positive outcomes in patients with treatment-resistant chronic-phase chronic myeloid leukemia (CP-CML) treated with ponatinib from the phase 2 OPTIC trial
    Meeting Abstract

    Apperley, J.; Cortes, J.; Jabbour, E.; Hochhaus, A.; Hughes, T.; Chuah, C.; de Lavallade, H.; Deininger, M.; Lipton, J. H.; Lomaia, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up
    Meeting Abstract

    Stopsack, K. H.; Chan, I. C.; Schmidt, E.; Panchot, A.; McNulty, S.; Schreiber, N. A.; Zhang, Y. W.; Penney, K. L.; Berger, M. F.; Diaz, L. A.; more...
    Cancer Prevention Research (2023)

    Fulltext@MSK | Save
  • Targeting JAK1 signaling for molecular prevention in clonal hematopoiesis
    Meeting Abstract

    Sánchez Vela, P.; Benitez, A. M.; Krishnan, A.; Kleppe, M.; Cai, S. F.; Levine, R. L.
    Cancer Prevention Research (2023)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemia
    Meeting Abstract

    Lewis, D. J.; Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN
    Meeting Abstract

    Munir, T.; Mato, A. R.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Patel, K.; Eyre, T. A.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
    Meeting Abstract

    Lewis, D. J.; Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutzu, K.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent BTK inhibitor in Richter transformation: Results from the BRUIN study
    Meeting Abstract

    Lewis, D. J.; Wierda, W. G.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M. S.; Ma, S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save